An individual site reorganization initiative involving the sale of land at the head office annex and the relocation of pharmaceutical and research functions to the head office and the R&D site in Iwaki, simultaneously strengthening capabilities and improving asset efficiency. The initiative covers recognition of a gain on sale and the consolidation of research functions to strengthen coordination.